Archive for the 'Bipolar' Category

Bipolar Depression Licence Application For Seroquel(R)

AstraZeneca has submitted an application to the Medicines and Healthcare products Regulatory Agency (MHRA) for a new licence for Seroquel(R) (quetiapine fumarate) in the UK for major depressive episodes in the framework of bipolar disorder. Quetiapine is currently licensed in the UK for the treatmen…

Astrazeneca Submits Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression, And Seroquel(R) For The Treatment Of Bipolar Depression

AstraZeneca announced that the company has submitted applications in the European Union (EU) under the Mutual Recognition Procedure (MRP) for once-daily SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, seeking approval for the treatment of manic episodes associated with bipolar disord…

ACADIA Announces Presentation Of goods On Pimavanserin Co-Therapy At The 14th Biennial Winter Workshop On On Schizophrenia And Bipolar Disorders

ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, nowadays announced that Murray Rosenthal, D.O.Original post by Dentistry News From Medical …

Scientists Discover Chemical Signature Of Manic Depression

People with manic depression have a distinct chemical signature in their brains, according to a new study. The research, published in the journal Molecular Psychiatry, may additionally indicate how the mood stabilisers used to treat the disorder counteract the changes in the brain that it appears to…

Study Suggests Risperidone faraway Acting Injection Combined With Standard Treatment Helped Delay instance To Relapse In Patients With Bipolar Disorder

Patients with frequently relapsing bipolar disorder had a meaningful delay in the date to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those wh…

New Analysis Demonstrates Efficacy Of Seroquel (Quetiapine Fumarate) Maintenance Treatment For Bipolar I Disorder

Results from a combined analysis of two enlarged term phase III clinical trials2,3 have shown that patients with bipolar I disorder who received treatment with quetiapine plus a mood stabiliser showed a 70% reduction in the risk of recurrence of a mood event (manic, mixed or depressed) compared to p…

New Analysis Highlights Potential Of SEROQUEL For expanded-term Treatment Of Bipolar Disorder

Results from a new analysis of two major clinical trials have shown that patients with bipolar disorder who received long-term treatment with SEROQUEL (quetiapine fumarate) plus a mood stabiliser were significantly less likely to have a mood event (manic, mixed or depressed) than patients on a mood…

Psychological Interventions Are Effective In Mood Swings

Jan Scott (Newcastle, UK) and Francesc Colom (Barcelona) have published a review of psychological interventions for bipolar disorder in the Jan 2008 issue of Psychotherapy and Psychosomatics.The aim of that review was to highlight gaps or limitations in applying evidence-based psychological therapie…

New Report Dispels Greatest Myths About Bipolar Disorder

New free report reveals that many individuals misunderstand bipolar disorder and have bought into “bipolar lies.” David Oliver, founder of Bipolar Central, has recently released a free report that uncovers and dispels various widely circulated myths about bipolar disorder. The report, entitled “10 G…

Most Psychiatric Patients Have More Than 1 Diagnosis, Study Finds

A new study by Rhode Island Hospital researchers reports that the majority of 2,300 psychiatry outpatients had more than one disorder when seeking treatment, and more than one-third had at least three disorders. The study is published in the February 2008 edition of the journal Psychological Medicin…

Astrazeneca Submits Supplemental New Drug Applications For Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression

AstraZeneca announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated wit…

Next Page »